Author:
Schmid Sabine,Früh Martin,Peters Solange
Reference10 articles.
1. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors;Westover;Ann Oncol,2018
2. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study;Ramalingam;Ann Oncol,2018
3. Papadimitrakopoulou VA, Wu Y, Han J, et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. European Society for Medical Oncology 2018; Munich, Germany; Oct 18–23, 2018 (abstr LBA51).
4. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study;Sequist;Lancet Oncol,2020
5. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献